Sign In
Buy EXEL
$51.60
+3.06 (+6.30%)
At Close: Jun 03, 2026
ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced its partner Ipsen received approval from the European Commission (EC) for CABOMETYX® (cabozantinib) in combination with
Exelixis: A Look At Its Potential
07:51am, Tuesday, 30'th Mar 2021
Exelixis is rapidly developing cabozantinib in many indications.
Exelixis (EXEL) Inks Collaboration Deal to Test XL092 Combo in UC
10:25am, Friday, 19'th Mar 2021
Exelixis (EXEL) signs a collaboration and supply agreement with Merck KGaA and Pfizer to investigate XL092 in combination with Bavencio for treating various forms of urothelial carcinoma.
Exelixis' XL092 To Be Tested In Combination With Bavencio In Urothelial Carcinoma
09:10am, Thursday, 18'th Mar 2021
Exelixis Inc (NASDAQ: EXEL) has announced a clinical trial collaboration and supply agreement with Germany's Merck KGaA and Pfizer Inc (NYSE: PFE) for the ongoing Phase 1b dose-escalation stud
Exelixis, Inc. (EXEL) Presents at Oppenheimer 31st Annual Healthcare Conference (Transcript)
01:33pm, Tuesday, 16'th Mar 2021
Exelixis, Inc. (EXEL) Presents at Oppenheimer 31st Annual Healthcare Conference (Transcript)
Why Is Exelixis (EXEL) Up 3.4% Since Last Earnings Report?
12:31pm, Friday, 12'th Mar 2021
Exelixis (EXEL) reported earnings 30 days ago. What's next for the stock?
Exelixis, Inc. (EXEL) CEO Mike Morrissey Presents at 2021 Barclays Global Healthcare Conference (Transcript)
03:00pm, Tuesday, 09'th Mar 2021
Exelixis, Inc. (EXEL) CEO Mike Morrissey Presents at 2021 Barclays Global Healthcare Conference (Transcript)
ALAMEDA, Calif. & SHANGHAI--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) and WuXi Biologics (“WuXi Bio”) (2269.HK) today announced the companies have entered into an exclusive license agreement
Exelixis' (EXEL) CEO Mike Morrissey on Cowen 41st Annual Health Care Conference - Transcript
08:35pm, Monday, 01'st Mar 2021
Exelixis' (EXEL) CEO Mike Morrissey on Cowen 41st Annual Health Care Conference - Transcript
ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (NASDAQ: EXEL) today announced that its partner Ipsen received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP), the s
Exelixis' Cabozantinib Gets Breakthrough Therapy Status In Differentiated Thyroid Cancer
11:11am, Thursday, 25'th Feb 2021
The FDA has granted Breakthrough Therapy Designation to Exelixis Inc's (NASDAQ: EXEL) CABOMETYX cabozantinib as a potential treatment for patients with differentiated thyroid cancer progressed fo
ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (NASDAQ: EXEL) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to cabozantinib (CABOMETYX
ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced that Michael M. Morrissey, Ph.D., the company's President and Chief Executive Officer will participate in a fireside cha
Got $500? 3 Smart Stocks You Can Buy Right Now
06:06am, Wednesday, 17'th Feb 2021
You don't need a mountain of cash to effectively build wealth on Wall Street.
Exelixis' Cabozantinib Shows Overall Objective Response Rates of 38% In Genitourinary Tumor Settings
09:06am, Tuesday, 16'th Feb 2021
Exelixis Inc (NASDAQ: EXEL) announces final data from Phase 1 trial sponsored and conducted by the U.S. National Cancer Institute (NCI), including seven expansion cohorts, evaluating cabozantinib
